Evidence map›Paper›PMID 36426370›Full record

ArticleFrontiers in immunology2022

Guillaume Larid, Adriana Delwail, Thomas Dalle, Philippe Vasseur, Christine Silvain, Jean-François Jégou, Franck Morel, Jean-Claude Lecron, Elisabeth Gervais

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Guillaume LaridRheumatology Department, CHU de Poitiers, Poitiers, France.
Adriana DelwailUMR 6041, 4CS, Université de Poitiers, Poitiers, France.
Thomas DalleUniversity of Poitiers, LITEC, Poitiers, France.
Philippe VasseurUniversity of Poitiers, LITEC, Poitiers, France.
Christine SilvainUniversity of Poitiers, LITEC, Poitiers, France.
Jean-François JégouUniversity of Poitiers, LITEC, Poitiers, France.
Franck MorelUniversity of Poitiers, LITEC, Poitiers, France.
Jean-Claude LecronUniversity of Poitiers, LITEC, Poitiers, France.
Elisabeth GervaisRheumatology Department, CHU de Poitiers, Poitiers, France.
Université de Poitiers · FRCentre Hospitalier Universitaire de Poitiers · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Psoriatic arthritis (PsA) and cutaneous psoriasis (PsO) are different phenotypes of psoriatic disease (PsD), whose underlying specific mechanisms remain incompletely understood. As cytokines are key elements to induce and tune up immune responses to drive inflammatory diseases, our objective was to assess whether clinical features, disease phenotype and PsA and PsO activity were associated with a particular Methods: Forty-eight patients (37 PsA and 11 PsO) and 11 healthy subjects (HS) were studied. Cytokine production by peripheral blood mononuclear cells (PBMC) that were either unstimulated, or stimulated with LPS or anti-CD3/CD28 antibodies, were analysed by multiplex assay in the culture supernatants. Results: Cytokine signature of PsD includes a high level of TNFα in supernatants of LPS-stimulated PBMC, higher levels of IL-6 and lower levels of IFN-γ and IL-17A after CD3-CD28 stimulation, as well as higher spontaneous IL-1RA and TNFα production compared to HS. High body mass index (BMI) was associated with lower levels of IL-1β, and metabolic syndrome with lower levels of IFN-γ after LPS stimulation. In PsD, dermatological activity was related with higher IL-17A level, while rheumatic activity was linked with lower levels of IFN-γ and TNFα. Comparing each PsD subtype to HS, IL-1β and IL-6 productions are higher when using LPS stimulation in PsO patients with higher levels of IL-1β and IL-1α in peripheral PsA patients after CD3/CD28 stimulation. LPS stimulation induced high levels of IL-17A in peripheral PsA compared to axial PsA. PsA patients with axial PsA share some features with PsO but shows a distinct cytokine pattern compared to peripheral PsA. Conclusion: PsO and the different PsA subtypes exhibit distinct

Indexed as

Arthritis, PsoriaticMetabolic SyndromePsoriasisCD28 AntigensHumansInterleukin-17Interleukin-6Leukocytes, MononuclearLipopolysaccharidesTumor Necrosis Factor-alphaCD28 AntigensInterleukin-17Interleukin-6LipopolysaccharidesTumor Necrosis Factor-alphacytokine signatureex vivo stimulationpsoriasispsoriatic arthritis (PsA)psoriatic disease

Identifiers

PMID36426370
PMCPMC9678922
OpenAlexW4308594561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.